Global Bladder Cancer Patient Insights and Epidemiology - 2016

  • ID: 3692137
  • Report
  • Region: Global
  • 110 pages
  • Epipatients
1 of 3
The latest survey Global Bladder Cancer Patient Insights and Epidemiology – 2016, provides insights into total Bladder Cancer patients on drug therapies in top 7 markets, Bladder Cancer treatable patients, and Bladder Cancer epidemiology in top 7 markets. Epipatients conducted an online survey with Bladder Cancer specialists, oncologists, and Bladder Cancer patients to identify the Bladder Cancer patients in top 7 markets who were treated by drug therapies. The research also identifies total Bladder Cancer patients’ on drug therapies by Bladder Cancer stages.
Chemotherapies for bladder cancer was given to patients in two different ways, Intravesical chemotherapy, and Systemic chemotherapy. Chemo drugs were used alone or in combination, depending on what they’re being used for, a patient’s overall health, and other factors. This study accurately determines and forecast Bladder Cancer patients who were on drug therapies in a given year. This research also provides insights into Bladder Cancer epidemiology including Bladder Cancer incidence and Bladder Cancer prevalence by Bladder Cancer stages I-IV.

Key Questions Answered:
- Countries: US, Japan, Germany, France, Italy, Spain, UK
- Bladder Cancer Incidence in top 7 markets by staging – Stage I, Stage II, Stage III, and Stage IV
- Bladder Cancer Prevalence in top 7 markets (10-year) by staging – Stage I, Stage II, Stage III, and Stage IV
- Bladder Cancer Treatable Patients in top 7 markets by staging – Stage I, Stage II, Stage III, and Stage IV
- Bladder Cancer Patients on drug therapies by stages – Stage I, Stage II, Stage III, and Stage IV
- Base Year – 2015, Historic from 2010 and forecast to 2025

Key Benefits:
This research will help analysts, healthcare providers, pharmaceutical companies, epidemiologists, clinical research organizations, universities, government agencies, and insurers to determine their study population. This research will help executives estimate Bladder Cancer market potential, Bladder Cancer drug therapies market potential, assess unmet need, patient share, market share, develop forecasting models, and build patient-based health management frameworks. The data presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Methodology
2. Bladder Cancer Patients Globally by Stages
2.1. Incidence
2.2. Prevalence
2.3. Treatable Patients
2.4. Patients on drug therapies
3. Bladder Cancer Patients in Germany by Stages
3.1. Incidence
3.2. Prevalence
3.3. Treatable Patients
3.4. Patients on drug therapies
4. Bladder Cancer Patients in France by Stages
4.1. Incidence
4.2. Prevalence
4.3. Treatable Patients
4.4. Patients on drug therapies
5. Bladder Cancer Patients in Italy by Stages
5.1. Incidence
5.2. Prevalence
5.3. Treatable Patients
5.4. Patients on drug therapies
6. Bladder Cancer Patients in Spain by Stages
6.1. Incidence
6.2. Prevalence
6.3. Treatable Patients
6.4. Patients on drug therapies
7. Bladder Cancer Patients in UK by Stages
7.1. Incidence
7.2. Prevalence
7.3. Treatable Patients
7.4. Patients on drug therapies
8. Bladder Cancer Patients in Japan by Stages
8.1. Incidence
8.2. Prevalence
8.3. Treatable Patients
8.4. Patients on drug therapies
9. Bladder Cancer Patients in US by Stages
9.1. Incidence
9.2. Prevalence
9.3. Treatable Patients
9.4. Patients on drug therapies
10. Glossary

1. Bladder Cancer Incidence by Stages, Global, 2010 - 2025
2. Bladder Cancer Prevalence by Stages, Global, 2010 - 2025
3. Bladder Cancer Treatable Patients by Stages, Global, 2010 - 2025
4. Total Bladder Cancer Patients on drug therapies by Stages, Global, 2010 – 2025
5. Bladder Cancer Incidence by Stages, Germany, 2010 - 2025
6. Bladder Cancer Prevalence by Stages, Germany, 2010 - 2025
7. Bladder Cancer Treatable Patients by Stages, Germany, 2010 - 2025
8. Total Bladder Cancer Patients on drug therapies by Stages, Germany, 2010 - 2025
9. Bladder Cancer Incidence by Stages, France, 2010 - 2025
10. Bladder Cancer Prevalence by Stages, France, 2010 - 2025
11. Bladder Cancer Treatable Patients by Stages, France, 2010 - 2025
12. Total Bladder Cancer Patients on drug therapies by Stages, France, 2010 - 2025
13. Bladder Cancer Incidence by Stages, Italy, 2010 - 2025
14. Bladder Cancer Prevalence by Stages, Italy, 2010 - 2025
15. Bladder Cancer Treatable Patients by Stages, Italy, 2010 - 2025
16. Total Bladder Cancer Patients on drug therapies by Stages, Italy, 2010 - 2025
17. Bladder Cancer Incidence by Stages, Spain, 2010 - 2025
18. Bladder Cancer Prevalence by Stages, Spain, 2010 - 2025
19. Bladder Cancer Treatable Patients by Stages, Spain, 2010 - 2025
20. Total Bladder Cancer Patients on drug therapies by Stages, Spain, 2010 - 2025
21. Bladder Cancer Incidence by Stages, UK, 2010 - 2025
22. Bladder Cancer Prevalence by Stages, UK, 2010 - 2025
23. Bladder Cancer Treatable Patients by Stages, UK, 2010 - 2025
24. Total Bladder Cancer Patients on drug therapies by Stages, UK, 2010 – 2025
25. Bladder Cancer Incidence by Stages, Japan, 2010 - 2025
26. Bladder Cancer Prevalence by Stages, Japan, 2010 - 2025
27. Bladder Cancer Treatable Patients by Stages, Japan, 2010 - 2025
28. Total Bladder Cancer Patients on drug therapies by Stages, Japan, 2010 – 2025
29. Bladder Cancer Incidence by Stages, US, 2010 - 2025
30. Bladder Cancer Prevalence by Stages, US, 2010 - 2025
31. Bladder Cancer Treatable Patients by Stages, US 2010 - 2025
32. Total Bladder Cancer Patients on drug therapies by Stages, US, 2010 - 2025

1. Bladder Cancer Incidence, Global, 2010 – 2025
2. Bladder Cancer Incidence – Stage I, Global, 2010 – 2025
3. Bladder Cancer Incidence – Stage II, Global, 2010 - 2025
4. Bladder Cancer Incidence – Stage III, Global, 2010 - 2025
5. Bladder Cancer Incidence – Stage IV, Global, 2010 – 2025
6. Bladder Cancer Prevalence, Global, 2010 - 2025
7. Bladder Cancer Prevalence – Stage I, Global, 2010 – 2025
8. Bladder Cancer Prevalence – Stage II, Global, 2010 - 2025
9. Bladder Cancer Prevalence – Stage III, Global, 2010 - 2025
10. Bladder Cancer Prevalence – Stage IV, Global, 2010 - 2025
11. Bladder Cancer Treatable Patients, Global, 2010 - 2025
12. Bladder Cancer Treatable Patients – Stage I, Global, 2010 – 2025
13. Bladder Cancer Treatable Patients – Stage II, Global, 2010 - 2025
14. Bladder Cancer Treatable Patients – Stage III, Global, 2010 - 2025
15. Bladder Cancer Treatable Patients – Stage IV, Global, 2010 - 2025
16. Bladder Cancer Patients on drug therapies, Global, 2010 - 2025
17. Total Bladder Cancer Patients on drug therapies – Stage I, Global, 2010 – 2025
18. Total Bladder Cancer Patients on drug therapies – Stage II, Global, 2010 – 2025
19. Total Bladder Cancer Patients on drug therapies – Stage III, Global, 2010 – 2025
20. Total Bladder Cancer Patients on drug therapies – Stage IV, Global, 2010 – 2025
21. Bladder Cancer Incidence by Stages, Germany, 2010 – 2025
22. Bladder Cancer Prevalence by Stages, Germany, 2010 – 2025
23. Bladder Cancer Treatable Patients by Stages, Germany, 2010 – 2025
24. Bladder Cancer Patients on drug therapies, Germany, 2010 - 2015
25. Bladder Cancer Incidence by Stages, France, 2010 – 2025
26. Bladder Cancer Prevalence by Stages, France, 2010 – 2025
27. Bladder Cancer Treatable Patients by Stages, France, 2010 – 2025
28. Bladder Cancer Patients on drug therapies, France, 2010 – 2025
29. Bladder Cancer Incidence by Stages, Italy, 2010 – 2025
30. Bladder Cancer Prevalence by Stages, Italy, 2010 – 2025
31. Bladder Cancer Treatable Patients by Stages, Italy, 2010 – 2025
32. Bladder Cancer Patients on drug therapies, Italy, 2010 – 2025
33. Bladder Cancer Incidence by Stages, Spain, 2010 – 2025
34. Bladder Cancer Prevalence by Stages, Spain, 2010 – 2025
35. Bladder Cancer Treatable Patients by Stages, Spain, 2010 – 2025
36. Bladder Cancer Patients on drug therapies, Spain, 2010 - 2015
37. Bladder Cancer Incidence by Stages, UK, 2010 – 2025
38. Bladder Cancer Prevalence by Stages, UK, 2010 – 2025
39. Bladder Cancer Treatable Patients by Stages, UK, 2010 – 2025
40. Bladder Cancer Patients on drug therapies, UK, 2010 – 2025
41. Bladder Cancer Incidence by Stages, Japan, 2010 – 2025
42. Bladder Cancer Prevalence by Stages, Japan, 2010 – 2025
43. Bladder Cancer Treatable Patients by Stages, Japan, 2010 – 2025
44. Bladder Cancer Patients on drug therapies, Japan, 2010 – 2025
45. Bladder Cancer Incidence by Stages, US, 2010 – 2025
46. Bladder Cancer Prevalence by Stages, US, 2010 – 2025
47. Bladder Cancer Treatable Patients by Stages, US, 2010 – 2025
48. Bladder Cancer Patients on drug therapies, US, 2010 - 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll